Samsung Bioepis OK'd to Start China Trial for Rare Disease Biosimilar

20:48 EST 14 Feb 2020 | ChinaBio Today

Samsung Bioepis, a biosimilar JV formed by Korea's Samsung and US-based Biogen, will start a China Phase III trial of a biosimilar to Soliris (eculizumab), a treatment for paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare genetic disease that affects stem cells causing them to produce defective blood cells. It usually strikes people between the ages of 35 and 40. Samsung Bioepis, which is conducting a global Phase III test of SB12, partnered China rights to eculizumab with AffaMed Therapeutics. AffaMed was formed by C-Bridge Capital to bring Samsung Bioepis biosimilars to China. More details....

Share this with colleagues:

Original Article: Samsung Bioepis OK'd to Start China Trial for Rare Disease Biosimilar


More From BioPortfolio on "Samsung Bioepis OK'd to Start China Trial for Rare Disease Biosimilar"

Quick Search

Relevant Topics

Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...